Showing results (1-10 of 359) with videos related to
Sort By:
Pageof 36
Trends in Molecular Medicine|May 14, 2016
Learning from PD-1 Resistance: New Combination StrategiesXia Bu, Kathleen M Mahoney, Gordon J FreemanNature Reviews. Immunology|January 23, 2020
The importance of exosomal PDL1 in tumour immune evasionDhouha Daassi, Kathleen M Mahoney, Gordon J FreemanClinical Therapeutics|April 1, 2015
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in MelanomaKathleen M Mahoney, Gordon J Freeman, David F McDermottNature Reviews. Drug Discovery|August 1, 2015
Combination cancer immunotherapy and new immunomodulatory targetsKathleen M Mahoney, Paul D Rennert, Gordon J FreemanTrends in Immunology|January 26, 2021
VISTA: A Mediator of Quiescence and a Promising Target in Cancer ImmunotherapyLong Yuan, Jahnavi Tatineni, Kathleen M Mahoney, et al.Cancer Immunology Research|October 12, 2021
Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune ResponsesXia Bu, Vikram R Juneja, Carol G Reynolds, et al.Nature Communications|May 16, 2023
PRMT1 mediated methylation of cGAS suppresses anti-tumor immunityJing Liu, Xia Bu, Chen Chu, et al.Cancer Immunology, Immunotherapy : CII|December 20, 2018
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppressionKathleen M Mahoney, Sachet A Shukla, Nikolaos Patsoukis, et al.Journal for Immunotherapy of Cancer|February 8, 2022
Soluble PD-L1 as an early marker of progressive disease on nivolumabKathleen M Mahoney, Petra Ross-Macdonald, Long Yuan, et al.Oncology (Williston Park, N.Y.)|November 12, 2014
Prognostic and predictive markers for the new immunotherapiesKathleen M Mahoney, Michael B AtkinsPageof 36